HF
ACRS icon

Halpern Financial’s Aclaris Therapeutics ACRS Stock Holding History

Halpern Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.75K Hold
1,500
– – ﹤0.01% 207
2024
Q2 		$1.65K Hold
1,500
– – ﹤0.01% 200
2024
Q1 		$1.88K Hold
1,500
– – ﹤0.01% 191
2023
Q4 		$1.68K Buy
+1,500
New +$4.58K ﹤0.01% 220

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Halpern Financial's ACRS Position: Q3 2024 in Review

Halpern Financial held its Aclaris Therapeutics (ACRS) position steady in Q3 2024 at 1,500 shares worth $1.75K. The position accounts for ﹤0.01% of the portfolio, ranked #207.

Halpern Financial first reported a position in ACRS in Q4 2023 and has held it in 4 quarters since. The position peaked at $1.88K in Q1 2024. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2024.

  • Halpern Financial held 1,500 shares of Aclaris Therapeutics worth $1.75K as of Q3 2024.
  • Halpern Financial left its Aclaris Therapeutics share count unchanged in Q3 2024.
  • Aclaris Therapeutics made up ﹤0.01% of Halpern Financial's portfolio in Q3 2024, its #207 holding.
  • Halpern Financial first reported a position in Aclaris Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • Halpern Financial's Aclaris Therapeutics position peaked at $1.88K in Q1 2024.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2024.

Based on Halpern Financial's 13F filing for Q3 2024, filed 4 Oct 2024.